Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 3/20 | 0.56 |
| ▸ | TRPV1 | Q8NER1 | 12/20 | 0.52 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA7 | P43166 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1463047 | 0.93 | KDR (0.57) | KDRTRPV1TMPRSS4CA1CA2 | |
| SCHEMBL3577666 | 0.87 | KDR (0.52) | KDRTRPV1 | |
| SCHEMBL5950271 | 0.85 | KDR (0.57) | KDRTRPV1CA1CA2CA7 | |
| SCHEMBL5950272 | 0.85 | GRIK1 (0.49) | KDRTRPV1TMPRSS4CA1CA2 | |
| SCHEMBL1463337 | 0.84 | KDR (0.54) | KDRTRPV1CA1CA2CA7 | |
| SCHEMBL4555014 | 0.83 | KDR (0.64) | KDRTRPV1CA1CA2CA7 | |
| SCHEMBL3581507 | 0.82 | KDR (0.51) | KDRTRPV1CA1CA2CA7 | |
| SCHEMBL3572047 | 0.82 | KDR (0.51) | KDRTRPV1 | |
| SCHEMBL5950227 | 0.82 | GRIK1 (0.57) | — | |
| SCHEMBL5949974 | 0.82 | GRIK1 (0.47) | CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663192-B1 | hERG1 CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | NEUROSEARCH AS (DK) | 2008-12-03 | — | — | EP | claimed |
| US-20060281794-A1 | Erg channel openers for the treatment of cardiac arrhythmias | NEUROSEARCH A/S (DK) | 2006-12-14 | — | — | US | claimed |
| CN-1845726-A | Erg channel openers for the treatment of cardiac arrhythmias | POSEIDON PHARMACEUTICALS AS (DK) | 2006-10-11 | — | — | CN | claimed |
| US-20060160856-A1 | Diarylurea derivatives and their use as chloride channel blockers | NEUROSEARCH A/S (DK) | 2006-07-20 | — | — | US | claimed |
| EP-1663192-A1 | ERG CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | Poseidon Pharmaceuticals A/S (DK) | 2006-06-07 | — | — | EP | claimed |
| WO-2005023237-A1 | ERG CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | POSEIDON PHARMACEUTICALS A/S (DK) | 2005-03-17 | — | — | WO | claimed |
| WO-2005023238-A1 | ERG CHANNEL OPENERS FOR THE TREATMENT OF HYPEREXCITABILITY-RELATED NEURONAL DISEASES | POSEIDON PHARMACEUTICALS A/S (DK) | 2005-03-17 | — | — | WO | claimed |
| US-20110071164-A1 | ERG CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | OLESEN SOEREN PETER | 2011-03-24 | — | — | US | disclosed |
| US-7851492-B2 | ERG channel openers for the treatment of cardiac arrhythmias | NEUROSEARCH A/S (DK) | 2010-12-14 | — | — | US | disclosed |
| EP-1663192-B1 | hERG1 CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | NEUROSEARCH AS (DK) | 2008-12-03 | — | — | EP | disclosed |
| US-20060281794-A1 | Erg channel openers for the treatment of cardiac arrhythmias | NEUROSEARCH A/S (DK) | 2006-12-14 | — | — | US | disclosed |
| CN-1845726-A | Erg channel openers for the treatment of cardiac arrhythmias | POSEIDON PHARMACEUTICALS AS (DK) | 2006-10-11 | — | — | CN | disclosed |
| US-20060160856-A1 | Diarylurea derivatives and their use as chloride channel blockers | NEUROSEARCH A/S (DK) | 2006-07-20 | — | — | US | disclosed |
| EP-1663192-A1 | ERG CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | Poseidon Pharmaceuticals A/S (DK) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005023238-A1 | ERG CHANNEL OPENERS FOR THE TREATMENT OF HYPEREXCITABILITY-RELATED NEURONAL DISEASES | POSEIDON PHARMACEUTICALS A/S (DK) | 2005-03-17 | — | — | WO | disclosed |
| WO-2005023237-A1 | ERG CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | POSEIDON PHARMACEUTICALS A/S (DK) | 2005-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281794-A1 | Erg channel openers for the treatment of cardiac arrhythmias | KCNJ2, KCNN3, KCNE1 | KDR 2568/4885TRPV1 88/4885TMPRSS4 795/4885 |
| US-20110071164-A1 | ERG CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | KCNJ2, KCNN3, KCNE1 | KDR 2568/4885TRPV1 88/4885TMPRSS4 795/4885 |
| US-20060160856-A1 | Diarylurea derivatives and their use as chloride channel blockers | KIT, ORAI1, CACNA1C | KDR 230/4885TRPV1 8/4885TMPRSS4 3042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.